Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* rheumatoid arthritis of \>=6 months duration diagnosed according to the revised 1987 ACR criteria;~* DAS28 of \>3.2;~* At screening either ESR \>=28 mm/h or CRP \>=1 mg/dL;~* Having received permitted DMARDs, 1 or more; current DMARD therapy must have been at a stable dose for at least 8 weeks prior to baseline.~Exclusion Criteria:~* major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following screening;~* functional class IV as identified by the ACR classification of functional status in RA;~* rheumatoid autoimmune disease other than RA;~* prior history of or current inflammatory joint disease other than RA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).